{"entity":{"id":"nct06571461","kind":"trial","name":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Canc","aka":[],"tldr":"A phase 3 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), tegafur, gimeracil and oteracil (S-1), gemcitabine and other drugs in pancreatic cancer, run by CSPC Ouyi Pharmaceutical Co., Ltd., not yet recruiting.","summary":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT06571461 by CSPC Ouyi Pharmaceutical Co., Ltd., with a registry enrolment figure of 408 participants, started 2024-09 and due to reach its primary completion in 2028-01. Interventions recorded: Liposomal Irinotecan; Oxaliplatin; S-1; Gemcitabine; Capecitabine. Conditions listed: Pancreatic Cancer. Primary outcome: Disease-free survival (DFS). Pancreatic eligibility wording from the registry: \"Histologically confirmed resected ductal pancreatic adenocarcinoma (including adenosquamous carcinoma)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06571461","url":"https://clinicaltrials.gov/study/NCT06571461"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["liposomal-irinotecan","capox","tegafur-gimeracil-oteracil","gemcitabine","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06571461","phase":"3","setting":"A Randomized, Open-label, Multi-center Phase III Clinical Study of Liposomal Irinotecan Combined With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine for Postoperative Adjuvant Treatment of Pancreatic Cancer","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","enrolled":408,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06571461/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/"},{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}